Swedish biotechnology company, Betagenon were ready to take their new drug candidate O304 to clinical trials. By applying adaptive design and delivering well-coordinated activities during the manufacturing, clinical trial management and bioanalysis stages, Ludof Pharmaceutical Ltd and Clinical Trial Consultants (CTC) were able to help Betagenon achieve a fast and flexible path to phase I clinical results and reach their important phase I milestone.